335 related articles for article (PubMed ID: 31651174)
1. PLGA Nanoparticles Codelivering siRNAs against Programmed Cell Death Protein-1 and Its Ligand Gene for Suppression of Colon Tumor Growth.
Kwak SY; Lee S; Han HD; Chang S; Kim KP; Ahn HJ
Mol Pharm; 2019 Dec; 16(12):4940-4953. PubMed ID: 31651174
[TBL] [Abstract][Full Text] [Related]
2. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches.
Won JE; Byeon Y; Wi TI; Lee CM; Lee JH; Kang TH; Lee JW; Lee Y; Park YM; Han HD
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35228265
[TBL] [Abstract][Full Text] [Related]
4. Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimine-Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth.
Kwak G; Kim D; Nam GH; Wang SY; Kim IS; Kim SH; Kwon IC; Yeo Y
ACS Nano; 2017 Oct; 11(10):10135-10146. PubMed ID: 28985469
[TBL] [Abstract][Full Text] [Related]
5. Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma.
Sugii N; Matsuda M; Okumura G; Shibuya A; Ishikawa E; Kaneda Y; Matsumura A
Cancer Sci; 2021 Jan; 112(1):81-90. PubMed ID: 33155337
[TBL] [Abstract][Full Text] [Related]
6. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
7. Melanoma Cancer Immunotherapy Using PD-L1 siRNA and Imatinib Promotes Cancer-Immunity Cycle.
Li C; Han X
Pharm Res; 2020 May; 37(6):109. PubMed ID: 32476052
[TBL] [Abstract][Full Text] [Related]
8. siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model.
Jung JY; Ryu HJ; Lee SH; Kim DY; Kim MJ; Lee EJ; Ryu YM; Kim SY; Kim KP; Choi EY; Ahn HJ; Chang S
Cells; 2021 Oct; 10(10):. PubMed ID: 34685714
[TBL] [Abstract][Full Text] [Related]
9. Laser Immunotherapy in Combination with Perdurable PD-1 Blocking for the Treatment of Metastatic Tumors.
Luo L; Zhu C; Yin H; Jiang M; Zhang J; Qin B; Luo Z; Yuan X; Yang J; Li W; Du Y; You J
ACS Nano; 2018 Aug; 12(8):7647-7662. PubMed ID: 30020768
[TBL] [Abstract][Full Text] [Related]
10. Co-immunizing with PD-L1 induces CD8
Guo S; Xiao P; Li B; Wang W; Wang S; Lv T; Xu X; Chen C; Huang L; Li Z; Tang L; Peng L; Wang H
Int Immunopharmacol; 2020 Jul; 84():106516. PubMed ID: 32334387
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous silencing of the A2aR and PD-1 immune checkpoints by siRNA-loaded nanoparticles enhances the immunotherapeutic potential of dendritic cell vaccine in tumor experimental models.
Karoon Kiani F; Izadi S; Ansari Dezfouli E; Ebrahimi F; Mohammadi M; Chalajour H; Mortazavi Bulus M; Nasr Esfahani M; Karpisheh V; Mahmoud Salehi Khesht A; Abbaszadeh-Goudarzi K; Soleimani A; Gholizadeh Navashenaq J; Ahmadi M; Hassannia H; Hojjat-Farsangi M; Shahmohammadi Farid S; Hashemi V; Jadidi-Niaragh F
Life Sci; 2022 Jan; 288():120166. PubMed ID: 34813798
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Blockade Mediated by a Small-Molecule Nanoinhibitor Targeting the PD-1/PD-L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer.
Zhang R; Zhu Z; Lv H; Li F; Sun S; Li J; Lee CS
Small; 2019 Dec; 15(49):e1903881. PubMed ID: 31702880
[TBL] [Abstract][Full Text] [Related]
13. Stromal Cell PD-L1 Inhibits CD8
O'Malley G; Treacy O; Lynch K; Naicker SD; Leonard NA; Lohan P; Dunne PD; Ritter T; Egan LJ; Ryan AE
Cancer Immunol Res; 2018 Nov; 6(11):1426-1441. PubMed ID: 30228206
[TBL] [Abstract][Full Text] [Related]
14. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.
Lussier DM; O'Neill L; Nieves LM; McAfee MS; Holechek SA; Collins AW; Dickman P; Jacobsen J; Hingorani P; Blattman JN
J Immunother; 2015 Apr; 38(3):96-106. PubMed ID: 25751499
[TBL] [Abstract][Full Text] [Related]
15. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity.
Cheng LS; Zhu M; Gao Y; Liu WT; Yin W; Zhou P; Zhu Z; Niu L; Zeng X; Zhang D; Fang Q; Wang F; Zhao Q; Zhang Y; Shen G
Cell Mol Biol Lett; 2023 May; 28(1):47. PubMed ID: 37259060
[TBL] [Abstract][Full Text] [Related]
16. Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer.
Gong X; Li X; Jiang T; Xie H; Zhu Z; Zhou F; Zhou C
J Thorac Oncol; 2017 Jul; 12(7):1085-1097. PubMed ID: 28478231
[TBL] [Abstract][Full Text] [Related]
17. Efficient PD-L1 gene silence promoted by hyaluronidase for cancer immunotherapy.
Guan X; Lin L; Chen J; Hu Y; Sun P; Tian H; Maruyama A; Chen X
J Control Release; 2019 Jan; 293():104-112. PubMed ID: 30476528
[TBL] [Abstract][Full Text] [Related]
18. Tumor perfusion enhancement by ultrasound stimulated microbubbles potentiates PD-L1 blockade of MC38 colon cancer in mice.
Li N; Tang J; Yang J; Zhu B; Wang X; Luo Y; Yang H; Jang F; Zou J; Liu Z; Wang Z
Cancer Lett; 2021 Feb; 498():121-129. PubMed ID: 33129956
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticle-Mediated Delivery of 2-Deoxy-D-Glucose Induces Antitumor Immunity and Cytotoxicity in Liver Tumors in Mice.
Sasaki K; Nishina S; Yamauchi A; Fukuda K; Hara Y; Yamamura M; Egashira K; Hino K
Cell Mol Gastroenterol Hepatol; 2021; 11(3):739-762. PubMed ID: 33191170
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM
Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
